1. Identify the most pertinent emerging therapeutics in lymphoma and multiple myeloma and implement practice-changing data into their clinical practice.
2. Summarize the benefits and limitations of CAR-T transplantation for patients with relapsed multiple myeloma
3. Explain the differences between LOXO-305 and the currently available BTK inhibitors
4. Identify CAR-T options with promising clinical trial data versus already FDA approved for lymphoma
5. Outline the current available evidence for CNS relapse in DLBCL
Event address for attendees: https://uwmadison.webex.com/uwmadison/onstage/g.php?MTID=eaef33b9897f676cd1f88bc3551ccf887
Session date:
01/06/2021 - 8:00am to 9:00am CST
Location:
Clinical Science Center, G5/119
600 Highland Ave
Madison, WI
53792
United States
See map: Google Maps
- 1.00 ACPE Contact Hours - Pharmacist
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC Contact Hours
- 1.00 University of Wisconsin–Madison Continuing Education Hours
Add to calendar:
Discloser List CME Internal Report
Presenter(s):
Dr. Vaishalee Kenkre
Dr. Saurabh Rajguru
Dr. Priyanka Pophali
Dr. Tim Schmidt
Dr. Natalie Callander